June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Synergism of mechanisms underlying early-stage changes in retina function after experimentally induced dyslipidemia and hyperglycemia
Author Affiliations & Notes
  • Peter Koulen
    Vision Research Center, Department of Ophthalmology, School of Medicine, University of Missouri Kansas City, Kansas City, Missouri, United States
    Department of Biomedical Sciences, School of Medicine, University of Missouri Kansas City, Kansas City, Missouri, United States
  • Genea Edwards
    Vision Research Center, Department of Ophthalmology, School of Medicine, University of Missouri Kansas City, Kansas City, Missouri, United States
  • Thomas P. Johnston
    Vision Research Center, Department of Ophthalmology, School of Medicine, University of Missouri Kansas City, Kansas City, Missouri, United States
    Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, Kansas City, Missouri, United States
  • Footnotes
    Commercial Relationships   Peter Koulen, None; Genea Edwards, None; Thomas Johnston, None
  • Footnotes
    Support  NIH grants RR027093, EY022774 and EY031248; departmental challenge grant by Research to Prevent Blindness
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3130. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Koulen, Genea Edwards, Thomas P. Johnston; Synergism of mechanisms underlying early-stage changes in retina function after experimentally induced dyslipidemia and hyperglycemia. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3130.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The study was designed to quantify retina function in a genetic mouse model of diabetes, in which sustained dyslipidemia was induced chemically. The goal of the study was to identify if dyslipidemia in the presence of hyperglycemia resulted in either a synergistic, or merely additive, exacerbation of retinopathy in the context of the two most clinically-relevant components or features of the metabolic syndrome.

Methods : Two cohorts of mice, C57BL/6 and C57BL/KsJ-db/db mice were divided into two groups each. One group of each strain received the triblock copolymer, poloxamer 407 (P-407), administered by intraperitoneal injection (“P-407” and “P-407 db/db” groups) with saline as a control in the remaining two groups (“saline” and “db/db” groups). Blood glucose, total cholesterol (TC) and total triglyceride (TG) levels were quantified using enzyme-based colorimetric assays. Retina function was measured using electroretinography (ERG) and visual acuity was determined behaviorally.

Results : TC and TG levels were normal in both saline controls and db/db mice, but were significantly elevated in the P-407 group (P<0.05), while levels of the same lipids were further elevated in the P-407 db/db group when compared to the P-407 group levels (P<0.0001). ERG measurements of scotopic retina function showed a significant decline in the b/a wave ratio of the P-407 and db/db groups and a further reduction for the P-407 db/db group when compared to controls (P<0.01). Similarly, behavioral assessment of the optomotor reflex indicated reduced visual acuity for both the P-407 and db/db groups and was further reduced in the P-407 db/db group when compared to either the P-407 or the db/db groups (P<0.001).

Conclusions : Dyslipidemia in the presence of hyperglycemia synergistically exacerbated disease severity of diabetic retinopathy. P-407 administration significantly elevated plasma TC and TG levels in wild-type and diabetic mice (db/db), but the resulting hyperlipidemia was more significantly pronounced in the diabetic mice. While elevated plasma lipid and blood glucose levels were individually correlated with a decline in retinal function, the combination of both exacerbated retina dysfunction. This model of combined hyperglycemia and dyslipidemia can be used to dissect individual contributions of features of the metabolic syndrome to the pathogenesis of diabetic retinopathy.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×